Literature DB >> 19475609

A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses.

Ruth Harbecke1, Michael N Oxman, Beth A Arnold, Charlotte Ip, Gary R Johnson, Myron J Levin, Lawrence D Gelb, Kenneth E Schmader, Stephen E Straus, Hui Wang, Peter F Wright, Constance T Pachucki, Anne A Gershon, Robert D Arbeit, Larry E Davis, Michael S Simberkoff, Adriana Weinberg, Heather M Williams, Carol Cheney, Luba Petrukhin, Katalin G Abraham, Alan Shaw, Susan Manoff, Joseph M Antonello, Tina Green, Yue Wang, Charles Tan, Paul M Keller.   

Abstract

A real-time PCR assay was developed to identify varicella-zoster virus (VZV) and herpes simplex virus (HSV) DNA in clinical specimens from subjects with suspected herpes zoster (HZ; shingles). Three sets of primers and probes were used in separate PCR reactions to detect and discriminate among wild-type VZV (VZV-WT), Oka vaccine strain VZV (VZV-Oka), and HSV DNA, and the reaction for each virus DNA was multiplexed with primers and probe specific for the human beta-globin gene to assess specimen adequacy. Discrimination of all VZV-WT strains, including Japanese isolates and the Oka parent strain, from VZV-Oka was based upon a single nucleotide polymorphism at position 106262 in ORF 62, resulting in preferential amplification by the homologous primer pair. The assay was highly sensitive and specific for the target virus DNA, and no cross-reactions were detected with any other infectious agent. With the PCR assay as the gold standard, the sensitivity of virus culture was 53% for VZV and 77% for HSV. There was 92% agreement between the clinical diagnosis of HZ by the Clinical Evaluation Committee and the PCR assay results. Published 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19475609      PMCID: PMC4217208          DOI: 10.1002/jmv.21506

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  24 in total

1.  Evaluation of LightCycler PCR for implementation of laboratory diagnosis of herpes simplex virus infections.

Authors:  M J Espy; T K Ross; R Teo; K A Svien; A D Wold; J R Uhl; T F Smith
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

Review 2.  Clinical virology in real time.

Authors:  Hubert G M Niesters
Journal:  J Clin Virol       Date:  2002-12       Impact factor: 3.168

3.  Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes.

Authors:  V N Loparev; K McCaustland; B P Holloway; P R Krause; M Takayama; D S Schmid
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

4.  Laboratory diagnosis of herpes zoster.

Authors:  A Sauerbrei; U Eichhorn; M Schacke; P Wutzler
Journal:  J Clin Virol       Date:  1999-09       Impact factor: 3.168

5.  Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR.

Authors:  V N Loparev; T Argaw; P R Krause; M Takayama; D S Schmid
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity.

Authors:  Y Gomi; T Imagawa; M Takahashi; K Yamanishi
Journal:  J Med Virol       Date:  2000-08       Impact factor: 2.327

7.  A real-time PCR assay for the detection of varicella-zoster virus DNA and differentiation of vaccine, wild-type and control strains.

Authors:  Graham A Tipples; David Safronetz; Michael Gray
Journal:  J Virol Methods       Date:  2003-11       Impact factor: 2.014

8.  Detection and genotyping of varicella-zoster virus by TaqMan allelic discrimination real-time PCR.

Authors:  Paul A Campsall; Nicholas H C Au; Julie S Prendiville; David P Speert; Rusung Tan; Eva E Thomas
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  New method of differentiating wild-type varicella-zoster virus (VZV) strains from Oka varicella vaccine strain by VZV ORF 6-based PCR and restriction fragment length polymorphism analysis.

Authors:  Michiko Takayama; Naohide Takayama
Journal:  J Clin Virol       Date:  2004-02       Impact factor: 3.168

10.  Identification and characterization of 20 immunocompetent patients with simultaneous varicella zoster and herpes simplex virus infection.

Authors:  K A Giehl; E Müller-Sander; M Rottenkolber; K Degitz; M Volkenandt; C Berking
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-02-25       Impact factor: 6.166

View more
  26 in total

1.  Presentation and management of herpes zoster (shingles) in the geriatric population.

Authors:  Kenneth R Cohen; Rebecca L Salbu; Jerry Frank; Igor Israel
Journal:  P T       Date:  2013-04

2.  Herpes zoster recurrences more frequent than previously reported.

Authors:  Barbara P Yawn; Peter C Wollan; Marge J Kurland; Jennifer L St Sauver; Patricia Saddier
Journal:  Mayo Clin Proc       Date:  2011-01-10       Impact factor: 7.616

3.  Long-term persistence of zoster vaccine efficacy.

Authors:  Vicki A Morrison; Gary R Johnson; Kenneth E Schmader; Myron J Levin; Jane H Zhang; David J Looney; Robert Betts; Larry Gelb; John C Guatelli; Ruth Harbecke; Connie Pachucki; Susan Keay; Barbara Menzies; Marie R Griffin; Carol A Kauffman; Adriana Marques; John Toney; Kathy Boardman; Shu-Chih Su; Xiaoming Li; Ivan S F Chan; Janie Parrino; Paula Annunziato; Michael N Oxman
Journal:  Clin Infect Dis       Date:  2014-11-20       Impact factor: 9.079

4.  Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.

Authors:  K E Schmader; M N Oxman; M J Levin; G Johnson; J H Zhang; R Betts; V A Morrison; L Gelb; J C Guatelli; R Harbecke; C Pachucki; S Keay; B Menzies; M R Griffin; C Kauffman; A Marques; J Toney; P M Keller; X Li; I S F Chan; P Annunziato
Journal:  Clin Infect Dis       Date:  2012-07-24       Impact factor: 9.079

5.  Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions.

Authors:  Sonja Thiele; Aljona Borschewski; Judit Küchler; Marc Bieberbach; Sebastian Voigt; Bernhard Ehlers
Journal:  Clin Vaccine Immunol       Date:  2011-05-11

Review 6.  Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer.

Authors:  Ian H Frazer; Myron J Levin
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

7.  Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

Authors:  Kenneth E Schmader; Myron J Levin; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino
Journal:  Clin Infect Dis       Date:  2012-01-30       Impact factor: 9.079

8.  Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.

Authors:  Myron J Levin; Kenneth E Schmader; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

Review 9.  Varicella zoster virus infection.

Authors:  Anne A Gershon; Judith Breuer; Jeffrey I Cohen; Randall J Cohrs; Michael D Gershon; Don Gilden; Charles Grose; Sophie Hambleton; Peter G E Kennedy; Michael N Oxman; Jane F Seward; Koichi Yamanishi
Journal:  Nat Rev Dis Primers       Date:  2015-07-02       Impact factor: 52.329

Review 10.  Herpes Zoster in the Older Adult.

Authors:  Amrita R John; David H Canaday
Journal:  Infect Dis Clin North Am       Date:  2017-12       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.